Q4 Inc. Releases Next Generation Investor Conference Features for its Rapidly Growing Investment Banking Client Base
9.12.2021 17:00:00 EET | Business Wire | Press release
Q4 Inc. (TSX: QFOR) (“Q4" or “the Company”), a leading capital markets communications platform, today announced the release of a suite of new features for its Capital Markets Event (“CME”) platform, launched earlier this year, and designed to provide virtual and in-person events for investment banking hosted investor conferences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005633/en/
Branded Event Registration (Graphic: Business Wire)
Starting in 2020, Q4 has experienced unprecedented demand from investment banks to create, host and deliver investor conferences for their buy-side clients. Since that time, Q4 has hosted thousands of market participants across investor conferences, reverse roadshows and corporate investor days and has established the bar by which all other capital markets and financial service events are measured. Building on its rapidly expanding footprint in the investment banking market, Q4 continues to enhance the CME platform in its partnership with corporate access teams at the world’s leading investment banks.
New capabilities recently added include sophisticated event registration, easy scheduling for meetings of all sizes, whether they are 1:1, 2:1 or larger group meetings, and meeting management data and analytics to assist corporate access teams successfully envision, plan and execute these critical events. These new features are embedded within Q4’s event platform, as well as API integrated into Zoom, Microsoft Teams and other technologies, delivering a seamless conference experience for all participants.
Specifically, these new features provide new registration functionality, which allows corporate and investor participants to submit their availability, and allows investors to indicate which corporate issuers they are interested in meeting with in priority order and preference for 1:1, 2:1 or a larger group meeting. This information is directly funneled to the internal scheduling tool, which makes scheduling significantly easier and updates automatically as participant availability changes.
Additionally, the Platform has new features that allow for meeting details to be easily added, edited and made available to all participants so that everyone is easily informed about the type of meeting, attendee information, and easy links for meeting access.
Finally, this upgrade provides critical data around scheduling as well as session and meeting attendance, helping corporate access teams determine which corporate issuers and investors may need additional meetings to enrich their experience, and require priority focus.
“We launched our Capital Markets Events (CME) platform with the vision of connecting all capital markets participants in their discovery, communications and engagement with each other,” said Darrell Heaps, CEO of Q4. “We are excited to enhance the capabilities of our platform, and deliver an elevated experience for our investment bank customers. We will continue to add features to our rapidly evolving solution, as we lead the digital transformation of corporate access engagements that connect all sides of the capital markets.”
To learn more about the Q4 CME platform, click here.
About Q4, Inc.
Q4 Inc. (Q4), is a leading capital markets communications platform that is transforming the way publicly traded companies, investors, and investment banks make decisions to efficiently discover, communicate, and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets customer relationship management solution, and shareholder and market analytics tools. The firm is a trusted partner to over 2,600 public companies as well as top tier investment banks. Q4 is based in Toronto, with offices in New York and London.
To learn more, visit: www.q4inc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005633/en/
Contact information
Media Inquiries:
Karen Greene media@q4inc.com
IR Inquiries:
Matt Tractenberg ir@q4inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom